Skip to main content
Frontiers in Microbiology logoLink to Frontiers in Microbiology
. 2016 Dec 23;7:2054. doi: 10.3389/fmicb.2016.02054

Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant Enterobacter cloacae

Piotr Majewski 1,*,, Piotr Wieczorek 1,, Dominika Ojdana 1, Anna Sieńko 1, Oksana Kowalczuk 2, Paweł Sacha 1, Jacek Nikliński 2, Elżbieta Tryniszewska 1
PMCID: PMC5179509  PMID: 28066375

Abstract

The growing incidence of multidrug-resistant (MDR) bacteria is an emerging challenge in modern medicine. The utility of carbapenems, considered “last-line” agents in therapy of infections caused by MDR pathogens, is being diminished by the growing incidence of various resistance mechanisms. Enterobacter cloacae have lately begun to emerge as an important pathogen prone to exhibiting multiple drug resistance. We aimed to investigate the molecular basis of carbapenem-resistance in 44 E. cloacae clinical strains resistant to at least one carbapenem, and 21 susceptible strains. Molecular investigation of 65 E. cloacae clinical strains was based on quantitative polymerase chain reaction (qPCR) allowing for amplification of ampC, ompF, and ompC transcripts, and analysis of nucleotide sequences of alleles included in MLST scheme. Co-operation of three distinct carbapenem resistance mechanisms has been reported—production of OXA-48 (5%), AmpC overproduction (97.7%), and alterations in outer membrane (OM) transcriptome balance. Carbapenem-resistant E. cloacae were characterized by (1.) downregulation of ompF gene (53.4%), which encodes protein with extensive transmembrane channels, and (2.) the polarization of OM transcriptome-balance (79.1%), which was sloped toward ompC gene, encoding proteins recently reported to possess restrictive transmembrane channels. Subpopulations of carbapenem-susceptible strains showed relatively high degrees of sequence diversity without predominant types. ST-89 clearly dominates among carbapenem-resistant strains (88.6%) suggesting clonal spread of resistant strains. The growing prevalence of pathogens resistant to all currently available antimicrobial agents heralds the potential risk of a future “post-antibiotic era.” Great efforts need to be taken to explore the background of resistance to “last resort” antimicrobials.

Keywords: carbapenem-resistance, outer membrane permeability, Enterobacter cloacae, MLST, AmpC

Introduction

An enormous adaptive capacity of Gram-negative multidrug-resistant (MDR) bacteria enables them to accumulate many different mechanisms of resistance to various antimicrobial agents (Nikaido, 2009; Poole, 2011). As a result occurrence of MDR pathogens considerably reduces the opportunities for an effective treatment of infectious diseases (Kaye and Pogue, 2015). Another vital epidemiological problem is the emergence and spread of novel mechanisms of antimicrobial drug resistance, especially among subpopulations of pathogens persisting in hospital environments (Hawkey and Jones, 2009; Davin-Regli and Pagès, 2015). The prevalence of those highly resistant microorganisms contributes significantly to prolonged hospitalization and increased mortality (Cerceo et al., 2016; MacVane, 2017). Increasing drug resistance among bacteria forces us to search for new therapeutic solutions and make decisions beyond standard treatment patterns (Fischbach, 2011; Tamma et al., 2012; Khameneh et al., 2016). However, the growing prevalence of pathogens resistant to most or even all currently available antimicrobial agents heralds the potential risk of a future “post-antibiotic era” (Falagas and Bliziotis, 2007; Majewski et al., 2012). According to the estimates published in a UK report on the development of antimicrobial resistance, in 2050, infections caused by MDR microorganisms could become one of the most important causes of mortality worldwide (10 million deaths per year), surpassing even the mortality rate currently caused by cancer (8.2 million deaths per year) (Review on Antimicrobial Resistance, 2014).

Carbapenems, broad spectrum agents with high bactericidal activity, are often referred to as “drugs of last resort” that retain activity against MDR Gram-negative bacteria (Papp-Wallace et al., 2011). However, the utility of carbapenems is being diminished by the growing incidence of various resistance mechanisms in bacteria (Giamarellou, 2010; Karaiskos and Giamarellou, 2014; Tängdén and Giske, 2015). Most frequently, carbapenem-resistance among Enterobacteriaceae is the result of various interacting β-lactam resistance strategies—namely, production of acquired carbapenemases, alteration in OM permeability, significantly increased production of chromosomally encoded β-lactamases (with slight carbapenemase activity, i.e., AmpC), and/or active efflux (Papp-Wallace et al., 2011). E. cloacae have lately begun to emerge as an important pathogen prone to exhibiting multiple drug resistance mechanisms and represents particularly high risk in the healthcare setting (Davin-Regli and Pagès, 2015). Therefore, we aimed to investigate the molecular basis of carbapenem-resistance in clinical strains of E. cloacae. Molecular characterization was based on qPCR, which was utilized in order to determine influence of chromosomal cephalosporinase (ampC) and porin-encoding (ompF, ompC) genes transcription level on carbapenem-resistance.

Materials and methods

Identification, susceptibility testing, and resistance detection

This study aimed to investigate the molecular basis of carbapenem resistance in 44 E. cloacae clinical strains resistant to at least one carbapenem, and 21 susceptible strains. Pathogens originated from patients hospitalized between 2007 and 2015 in University Hospital and the Children's University Hospital of Bialystok. Biochemical identification was performed using ID-GN cards and automated the VITEK2 system (bioMérieux, Marcy l'Etoile, France) following manufacturer's guidelines. Antimicrobial activity of carbapenems (ertapenem, meropenem, imipenem, doripenem, biapenem) and cephalosporins (cefepime, cefotaxime, ceftazidime, ceftriaxone) was investigated with the use of the microdilution method in Mueller-Hinton Broth (Oxoid, Basingstoke, UK). Results were interpreted in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (The European Committee on Antimicrobial Susceptibility Testing, 2015). Synergy testing of carbapenems (meropenem and imipenem) with β-lactamase inhibitors, double-disk synergy test for extended-spectrum β-lactamase (ESBL) screening (Mueller-Hinton with and without cloxacillin), and a biochemical carbapenemase assay (CARBA-NP test II) were performed, as described previously (Dortet et al., 2012). Polymerase chain reaction (PCR) experiments were done in order to detect various carbapenemase-encoding genes. Oligonucleotides and thermal conditions are presented in Table 1.

Table 1.

Oligonucleotides used in polymerase chain reactions.

Oligonucleotide Sequence (5′–3′) Product Application References
OXA−48−like_F ATC ACA GGG CGT AGT TGT GC 182 bp PCR This study
OXA−48−like_R GCG TCT GTC CAT CCC ACT TA
NMC-A/IMI_F CAA TGG CAG GAT TGG TGT CT 412 bp PCR This study
NMC-A/IMI_R CTC ATC GCC TGG AAT AGC TG
OXA-51-like_F GGA AGT GAA GCG TGT TGG TT 224 bp PCR This study
OXA-51-like_R CCC AAC CAC TTT TTG CGT AT
OXA-58-like_F AAT TGG CAC GTC GTA TTG GT 231 bp PCR This study
OXA-58-like_R CCC CTC TGC GCT CTA CAT AC
GES_F CGA AAA AGC AGC TCA GAT CG 184 bp PCR This study
GES_R GTC CGG CCC ATA TGA AAG TT
VIM_F GAT GGT GTT TGG TCG CAT A 390 bp PCR Ellington et al., 2007
VIM_R CGA ATG CGC AGC ACC AG
KPC_F ATG GCC GCT GGC TGG CTT TT 785 bp PCR Sacha et al., 2012
KPC_R CGG CCT CGC TGT GCT TGT TCA
IMP_F GGA ATA GAG TGG CTT AAY TCT C 188 bp PCR Ellington et al., 2007
IMP_R CCA AAC YAC TAS GTT ATC T
NDM_F GAC CGA TGA CCG CCC AG 372 bp PCR Findlay et al., 2012
NDM_R GAC TTG GCC TTG CTG TCC TT
ampC_F CTC ACT TAA GCA GGG CAT CG 167 bp qPCR This study
ampC_R TCA CTT CTA CCA CGG GCA AC
ompF_F GAC GCA GGC TCC TTC GAC TA 172 bp qPCR This study
ompF_R CAA CCA GGC CGA AGA AGT TG
ompC_F CTA CGG CGT TGT TTA CGA TGT G 150 bp qPCR This study
ompC_R AGA CCA TCA ACC AGA CCG AAG A
rpoB_F TCC ACT CAT GAC GGA CAA CG 170 bp qPCR This study
rpoB_R GCC ATG AAC CAC GGT AAG GA

Detection of carbapenemase-encoding genes was carried out in the following thermal conditions—5 min of initial denaturation at 95°C, 30 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 30 s, and elongation at 72°C for 30–40 s, followed by final elongation at 72°C for 5 min; Analysis of mRNA levels was carried out with the following thermal conditions—5 min of initial denaturation at 95°C, 35 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 30 s, and elongation at 72°C for 30 s, followed by analysis of melting profiles of obtained products.

Analysis of gene expression patterns

Overnight cultures of E. cloacae isolates on Luria Broth (A&A Biotechnology, Gdynia, Poland) were centrifuged and subjected to total RNA isolation procedure (Total RNA Mini Plus, A&A Biotechnology, Gdynia, Poland). Traces of DNA were removed with the use of DNase and silica columns (Clean-Up RNA Concentrator, A&A Biotechnology). Quantity of total RNA extracts was examined with the use of spectrophotometer (NanoDrop™ 2000, Thermo Fisher Scientific, Waltham, USA). Synthesis of cDNA was performed with the use of 1.0 μg of total RNA, 200U of SuperScript® IV reverse transcriptase, 4 μl of concentrated Super-Script buffer (Thermo Fisher Scientific, Waltham, USA), 100 μM of deoxynucleotide triphosphates (dNTPs), 50 μM of random hexamers, 40U of RNase inhibitor and 100 μM of dithiothreitol (DTT) (A&A Biotechnology).

Real-time quantitative PCR was performed using SYBR® Green I assay with analysis of dissociation curve (Real-Time 2xPCR Master Mix SYBR C, A&A Biotechnology) on an MxPro 3005P thermal cycler (Agilent Technologies, Waldbronn, Germany). Oligonucleotides and thermal conditions are presented in Table 1. Efficiency of particular reactions were established by standard curve method. Results were calculated by efficiency corrected method described by Pfaffl (2001). Analysis of mRNA levels was carried out in triplicate. Moreover, the Liquid Handling Robot QIAgility (Qiagen, Hilden, Germany) was utilized to set up real-time quantitative PCR. E. cloacae ATCC 700323 (CL7094, Oxoid Culti-Loops®, Basingstoke, UK) was used as a reference in the analysis of relative changes in gene expression.

During the analysis of relative changes in gene expression level, a logarithmic transformation of fold changes (FC—fold change) was applied for statistical purposes. Quantitative (FC) and categorical data were utilized to assess differences between carbapenem-resistant and carbapenem-susceptible subpopulations. For the purpose of categorization in the analysis of relative increase of AmpC β-lactamase expression level, a threshold of log2FC ≥ 2.0 was adopted. For the purpose of qualitative directional analysis of relative changes in OM protein-encoding genes, three ranges of values were adopted: (1) log2FC ≤ −1.0 for relatively increased expression level, (2) log2FC ≥ 1.0 for relatively decreased expression level, and (3) log2FC ranging from −1.0 to 1.0 for relatively indifferent expression level.

OM transcriptome profiles of tested strains were established after the interpretation of relative changes in porin-encoding gene expression level, in accordance with accepted thresholds. OM transcriptome profiles were created in order to illustrate the relationship between the transcript level of two major porins and the phenotype. Nine possible OM transcriptome variants were adopted (Table 2).

Table 2.

Distribution of OM transcriptome profile among E. cloacae strains.

OM transcriptome profile Polarization CARBR CARBS
n [%] n [%]
ompF(↓):ompC(↓) (I) 1 2.3 1 4.8
ompF(↓):ompC(↑) (II) OmpC 11 25.6 1 4.8
ompF(↓):ompC(–) (III) OmpC 11 25.6 2 9.5
ompF(–):ompC(↑) (IV) OmpC 12 27.9 4 19
ompF(–):ompC(↓) (V) OmpF 3 7.0 4 19
ompF(–):ompC(–) (VI) 4 9.3 6 28.6
ompF(↑):ompC(↓) (VII) OmpF 0 0 2 9.5
ompF(↑):ompC(↑) (VIII) 1 2.3 0 0
ompF(↑):ompC(–) (IX) OmpF 0 0 1 4.8

OM transcriptome profiles of tested strains were established after the interpretation of relative changes in porin-encoding gene expression level, in accordance with accepted thresholds.

Polarization index (PI—quotient of FCompF and FCompC) was developed for the quantitative measurement of OmpC-directed OM transcriptome polarization which could have a potential link to the development of resistance to β-lactams. Polarization index differences between groups were proven to be statistically significant (Table 3, p = 0.0001). Moreover, the interplay between OmpC-directed OM transcriptome polarization and overexpression of AmpC β-lactamase, as well as its influence on susceptibility patterns was estimated by derivative derepression-polarization index (DPI − log2FCampC + log2PI). Correlation between MIC values of carbapenems and DPI values was assessed by the Pearson correlation test (Figure 1, p < 0.05).

Table 3.

Outer membrane transcriptome polarization index (PI) among E. cloacae strains.

FCompF/FCompC
# #
1 R1 102.6 33 R35 3.8
2 R2 2.4 34 R36 5.7
3 R3 7.7 35 R37 3.3
4 R5 0.5 36 R38 3.6
5 R6 2.7 37 R39 6
6 R7 0.4 38 R40 9
7 R8 12 39 R41 4
8 R9 5.7 40 R42 5.3
9 R10 6.3 41 R43 3
10 R11 12.5 42 R44 2.4
11 R12 11.7 43 R69 9.6
12 R13 24 44 S45 6.5
13 R14 6.5 45 S46 12.5
14 R15 8.5 46 S47 2.4
15 R16 15.5 47 S48 1.1
16 R17 20.8 48 S49 0.6
17 R18 34.1 49 S52 2.1
18 R19 2.1 50 S53 0.01
19 R20 6.5 51 S54 0.01
20 R21 1.2 52 S55 2.3
21 R22 2.8 53 S56 0.003
22 R23 1.6 54 S57 1.7
23 R24 23 55 S58 0.7
24 R25 53.7 56 S59 0.8
25 R26 1.6 57 S61 0.9
26 R28 3 58 S62 16.3
27 R29 0.5 59 S63 0.5
28 R30 1.6 60 S64 1.2
29 R31 3.6 61 S65 0.9
30 R32 0.6 62 S66 2.7
31 R33 5.5 63 S67 0.1
32 R34 10 64 S68 1.4

Figure 1.

Figure 1

Correlation between derepression-polarization index (DPI) and MICs among E. cloacae strains. Correlations between log-transformed MIC values and DPI were assessed with use of Pearson correlation test.

Strain typing

Investigation of genetic relatedness was performed according to multi-locus sequence analysis scheme developed by Miyoshi-Akiyama et al. (2013). Analysis of nucleotide sequences was undertaken using Sanger sequencing (BrightDye™ Terminator Sequencing Kit, Nimagen, Nijmegen, Netherlands) and subsequent capillary electrophoresis using the 3500 Genetic Analyzer (Applied Biosystems, Foster City, USA). Any novel alleles or sequence types (STs) were assigned and stored in the PubMLST domain (http://pubmlst.org). Phylogenetic analysis with the use of concatenated sequences and maximum parsimony method (BioNumerics 7.6—evaluation license, Applied Maths, Sint-Martens-Latem, Belgium) were utilized to determine the degree of relatedness between particular strains of E. cloacae.

Results

Antimicrobial susceptibility testing of 65 clinical strains of E. cloacae was performed with the use of the broth microdilution method (Table 4). Pathogens were divided into two groups according to their susceptibility—44 E. cloacae clinical strains resistant to at least one carbapenem (CARB-R), and 21 susceptible strains (CARB-S). The range of obtained MICs of particular antimicrobial agents was illustrated by MIC50 and MIC90 values. Descriptive statistics considering antimicrobial susceptibility testing are presented in Table 5.

Table 4.

MIC values (mg/L) of β−lactams against the clinical E. cloacae strains.

ETP IMP MEM DOR BIA CAZ FEP CTX TRX
R1 128 8 16 8 8 512 32 512 2048
R2 32 4 16 4 4 512 256 1024 2048
R3 64 4 4 4 1 8 256 512 512
R4 16 2 4 1 0.25 4 256 256 512
R5 32 4 8 2 2 128 512 2048 2048
R6 64 4 8 4 4 256 512 2048 4096
R7 32 2 2 1 1 256 32 1024 2048
R8 8 0.25 0.5 0.25 0.25 512 32 1024 4096
R9 8 0.5 1 0.25 0.125 256 128 1024 2048
R10 8 0.5 0.25 0.125 0.125 256 64 1024 2048
R11 8 0.5 0.5 0.25 0.125 256 128 1024 2048
R12 8 0.5 1 0.5 0.25 256 128 1024 2048
R13 128 8 8 4 4 512 64 1024 4096
R14 8 0.5 1 0.25 0.125 256 32 512 2048
R15 16 1 4 1 1 512 64 1024 4096
R16 8 0.5 0.5 0.25 0.125 512 256 1024 4096
R17 32 2 2 0.5 0.25 512 16 1024 2048
R18 8 0.5 0.5 0.5 0.125 128 8 256 1024
R19 4 0.25 0.25 0.125 0.06 128 16 256 512
R20 8 0.5 0.5 0.5 0.5 512 32 2048 4096
R21 16 1 4 1 1 512 32 1024 2048
R22 8 1 1 0.25 0.125 512 128 1024 2048
R23 8 0.5 0.5 1 0.25 256 128 512 1024
R24 8 0.5 0.5 0.25 0.25 256 32 512 1024
R25 8 1 1 2 1 1024 64 2048 4096
R26 4 0.25 0.25 0.25 0.125 128 8 512 1024
R28 2 0.25 0.125 0.125 0.125 256 32 512 1024
R29 2 0.25 0.125 0.125 0.125 128 128 256 512
R30 8 0.5 0.5 0.25 0.25 128 8 512 1024
R31 8 0.5 0.5 0.5 0.125 256 128 1024 2048
R32 8 0.5 0.25 0.25 0.25 64 16 512 1024
R33 8 0.5 0.25 0.25 0.25 256 16 512 1024
R34 8 0.5 0.25 0.25 0.125 256 128 512 2048
R35 4 0.5 0.25 0.25 0.125 256 32 512 1024
R36 4 0.25 0.25 0.25 0.125 512 16 512 1024
R37 2 0.25 0.125 0.5 0.5 256 64 512 2048
R38 8 0.5 0.5 0.5 0.5 512 64 1024 4096
R39 4 0.25 0.25 0.125 0.125 256 8 512 1024
R40 4 1 0.5 0.25 0.5 256 16 512 1024
R41 4 0.25 0.5 0.25 0.5 256 32 512 1024
R42 4 0.25 1 0.25 0.125 256 32 512 2048
R43 2 0.25 0.25 0.125 0.125 256 512 2048 4096
R44 8 0.5 0.5 0.5 0.5 512 64 1024 2048
R69 4 0.5 0.25 0.25 0.25 256 32 512 512
S45 0.06 0.25 0.06 0.03 0.03 0.25 0.125 0.25 0.5
S46 0.125 0.06 0.125 0.03 0.03 32 64 512 512
S47 0.5 0.25 0.06 0.03 0.06 64 16 512 1024
S48 0.5 0.25 0.03 0.06 0.06 128 1 8 8
S49 0.06 0.25 0.015 0.03 0.06 64 32 1024 1024
S52 0.03 0.25 0.015 0.03 0.06 8 64 2048 1024
S53 0.008 0.125 0.015 0.03 0.03 0.25 0.125 0.125 0.125
S54 0.008 0.25 0.015 0.06 0.03 0.06 0.125 0.06 0.125
S55 0.015 0.25 0.015 0.03 0.06 0.25 0.125 0.125 0.25
S56 0.008 0.25 0.015 0.03 0.03 0.5 0.125 0.25 0.5
S57 0.03 0.25 0.03 0.03 0.06 0.5 0.25 1 0.5
S58 0.25 0.25 0.06 0.06 0.06 1 0.125 1 16
S59 0.03 0.25 0.03 0.03 0.03 0.125 0.125 0.125 0.25
S61 0.25 0.25 0.06 0.03 0.03 2 32 128 256
S62 0.06 0.06 0.015 0.03 0.03 0.5 0.25 0.5 1
S63 0.5 0.5 0.125 0.125 0.06 128 1 16 16
S64 0.5 0.25 0.125 0.06 0.06 2 0.25 4 4
S65 0.03 0.125 0.03 0.03 0.03 256 4 32 64
S66 0.5 0.25 0.125 0.06 0.06 256 1 32 64
S67 0.125 0.25 0.03 0.06 0.06 16 0.125 16 16
S68 0.03 0.25 0.03 0.03 0.03 0.125 0.125 0.25 0.25

ETP, ertapenem; IMP, imipenem; MEM, meropenem; DOR, doripenem; BIA, biapenem; CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; TRX, ceftriaxone; Presented data is expressed in in mg/L.

Table 5.

Descriptive statistics considering antimicrobial susceptibility of tested Enterobacter cloacae strains.

Group Agent Range Median Mode MIC50 MIC90
CARB−R ETP 2–128 8 8 32 8
IMP 0.25–8 0.5 0.5 4 0.5
MEM 0.125–16 0.5 0.5 8 0.5
DOR 0.125–8 0.25 0.25 4 0.25
BIA 0.06–8 0.25 0.125 2 0.25
CAZ 4–1024 256 256 512 256
FEP 8–512 48 32 256 32
CTX 256–2048 512 512 2048 512
TRX 512–4096 2048 2048 4096 2048
CARB−S ETP 0.008–0.5 0.06 0.03 0.5 0.06
IMP 0.06–0.5 0.25 0.25 0.25 0.25
MEM 0.008–0.125 0.03 0.015 0.125 0.03
DOR 0.03–0.125 0.03 0.03 0.06 0.03
BIA 0.03–0.06 0.045 0.06 0.06 0.06
CAZ 0.06–256 1.5 0.25 256 2
FEP 0.125–64 0.25 0.125 64 0.25
CTX 0.06–2048 2.5 0.125 512 1
TRX 0.125–1024 6 0.25 1024 4

ETP, ertapenem; IMP, imipenem; MEM, meropenem; DOR, doripenem; BIA, biapenem; CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; TRX, ceftriaxone; Presented data is expressed in in mg/L.

Phenotypic double-disk synergy test revealed similar rates of ESBL occurrence in both carbapenem-resistant (41%, n = 18) and carbapenem-susceptible (48%, n = 10) subpopulations of clinical E. cloacae strains (Table 6). Synergy testing with the use of carbapenemase inhibitors was negative for all tested E. cloacae clinical strains. However, the CARBA-NP II biochemical assay revealed carbapenemase activity in two carbapenem-resistant strains (5%, n = 2), particularly R3 and R4. PCR and Sanger sequencing enables us to classify carbapenemase as a class D enzyme, namely OXA-48 in both carbapenemase-positive strains.

Table 6.

Molecular characteristic of clinical E. cloacae strains.

graphic file with name fmicb-07-02054-i0001.jpg

Strains R3 and R4 possessed blaOXA−48 carbapenemase; Arrows represents up− and down−regulation of particular transcripts.

*Detailed characteristics of OM transcriptome profiles is available in Table 2.

In the following step, an analysis of relative changes in the expression levels of genes encoding general OM proteins responsible for β-lactam penetration (ompC and ompF) as well as chromosomal AmpC β-lactamase was performed. Numerical data illustrating directional relative changes in gene expression levels are presented in Table 6.

Relative changes in the blaampC transcript levels in the examined E. cloacae subpopulations were unidirectional. Most pathogens from the CARB-R subpopulation (97.7%) showed derepression of chromosomal class C β-lactamase. Carbapenemase-producing E. cloacae R4 was the only nonderepressed strain accounted for in the carbapenem-resistant group. The range of log2FCampC values in the CARB-R group was between 10.0 and 0.2, with a median value at 4.35. In the CARB-S subpopulation, reported relative changes in ampC gene expression fell within a range of 3.0–0.4, with a median value of 0.73. Analysis of relative changes in ampC expression level showed statistically significant variation between CARB-R and CARB-S subpopulations (p < 0.000001).

During the analysis of relative changes in transcript levels (ompF and ompC) among tested E. cloacae strains, bidirectional changes were reported. Strain R4 was excluded from OM transcript level analysis due to lack of ompF, and ompC amplification, despite the confirmed oligonucleotide specificity on gDNA of all tested strains. Most of the CARB-R strains showed relative decrease in ompF expression level (53.4%). Interestingly, strains exhibiting a decrease in ompF expression level were present also in the CARB-S subpopulation (19%), although these pathogens did not develop simultaneous AmpC derepression. The range of log2FCompF values in the CARB-R group was between −2.18 and 5.68, with a median value at 1.03. In the CARB-S subpopulation, reported relative changes in ompC gene expression fell within a range of −3.15 to 4.02, with a median value of 0.23. Analysis of relative changes in ompF gene expression showed statistically significant differences between tested E. cloacae subpopulations (p < 0.0006). The relative decrease in ompC expression was present with much stronger frequency in CARB-S (33.3%), as compared to CARB-R (9%). However, most of the CARB-R strains (55.8%) were characterized by relatively increased ompC gene expression level. The range of log2FCompC values in the CARB-R group was between −3.19 and 2.15, with a median value at −1.03. In the CARB-S subpopulation, reported relative changes in ompC gene expression level fell within a range of −2.39 to 7.22, with a median value of 0.06. Analysis of relative changes in ompC gene expression showed statistically significant differences between tested E. cloacae subpopulations (p < 0.008).

Nine OM transcriptome profiles created in order to illustrate the relationship between the transcript level of two major porins and the phenotype are presented in Tables 5, 6. OM transcriptome profiles II, III, and IV with ompC-directed polarization (narrow transmembrane channel) were characteristic for the CARB-R subpopulation and constituted a total of 79.1%. In CARB-S strains OM transcriptome profiles V, VII, and IX with ompF-directed polarization accounted for 33.3%. Profile VI with unaltered levels of both porin-encoding genes was assigned for 28.6% of CARB-S strains. Polarization indices representing quantitative measurement of OmpC-directed OM transcriptome polarization, which could have a potential link to the development of resistance to β-lactams, are presented in Table 3 (p = 0.0001). Moreover, the interplay between OmpC-directed OM transcriptome polarization and overexpression of AmpC β-lactamase, as well as its influence on MIC values estimated by derivative derepression-polarization index (DPI − log2FCampC + log2PI). Correlations between MIC and DPI values assessed by the Pearson correlation test are presented in Figure 1 (p < 0.05).

Phylogenetic analysis with the use of concatenated sequences and maximum parsimony method showed a degree of relatedness between particular strains of E. cloacae (Figure 2, Table 6). A group of CARB-S strains was characterized by a high diversity of STs, among which we failed to specify the dominant group. Carbapenem-susceptible strains were assigned to ST-133 (14.3%), ST-335, ST-45, ST-108, ST-168 (9.5%), and single cases of ST-752, ST-753, ST-754, ST-110, ST-79, ST-407, ST-68, ST-89, and ST-90 (1.9%). Among CARB-R E. cloacae strains, we observed a clearly dominating ST-89 (88.6%), suggesting clonal spread of carbapenem-resistant pathogens among patients of the University Hospital and the University Children's Hospital of Bialystok. The remaining strains of CARB-R E. cloacae belonged to the individual, relatively closely related ST-751 and ST-329 (2.3%); more distant types ST-750 and ST-121, as well as ST-186, located far away from the entire pool of tested E. cloacae strains.

Figure 2.

Figure 2

Genetic relatedness of CARB-R and CARB-S E. cloacae strains. Carbapenem-resistant and carbapenem-susceptible strains has been represented by red and green segments, respectively. Resolution of individual nodes in the phylogenetic tree represents the number of strains belonging to a particular ST. The number of strains attributable to a particular ST is also indicated by the division of each node into the proper amount of segments. Genetic distance between different STs is reflected by the numerical values posted at the branches of the phylogenetic tree.

Discussion

We identified three distinct mechanisms that may contribute to the phenotype of resistance to carbapenems among tested E. cloacae subpopulations. A unique mechanism in the performed analysis was identified in two CARB-R strains (5%). Two exceptional strains, R3 and R4, possess the ability to produce acquired OXA-48 carbapenemase. The presence of OXA-48-type carbapenemase in E. cloacae is not a phenomenon widely described in the literature. Strain R3 was the first case of OXA-48 carbapenemase-producing E. cloacae infection in Poland (Majewski et al., 2014a).

In the remaining part of the CARB-R E. cloacae subpopulation, we observed the coexistence of two distinct mechanisms of resistance related to β-lactams: overproduction of AmpC cephalosporinase, and alterations in the expression profile of porin-encoding genes. Constitutive overproduction of the chromosomal AmpC cephalosporinase was typical for most CARB-R strains (97.7%). The exceptional strain R4 expressed inducible AmpC, and was also capable of producing OXA-48 carbapenemase. Strains belonging to the CARB-S control group were able to produce AmpC cephalosporinase at low level (90.4%), except for two strains, S53 and S54 (see explanation below).

The second mechanism associated with the development of resistance to carbapenems in tested E. cloacae subpopulations is alterations in the OM transcriptome profile responsible for permeability of the OM. A large percentage of carbapenem-resistant strains (53.4%) were characterized by a relative decrease in the expression level of ompF, gene encoding an protein essential for efficient β-lactam penetration into periplasmic space (Delcour, 2009; James et al., 2009; Ziervogel and Roux, 2013). Another trend identified in the CARB-R group was the altered balance of OM transcriptome (79.1%), which was polarized toward ompC gene, encoding proteins recently reported to possess restrictive transmembrane channels (James et al., 2009). On the other hand, the ompF-directed transcriptome profile was prevalent among CARB-S strains (33.3%) suggesting that permeability was determined by a proteins with transmembrane channels favorable for β-lactam penetration. The second group of CARB-S strains was characterized by a relatively unchanged OM transcriptome profile (28.6%).

Carbapenem-susceptible E. cloacae strains served as an important point of reference during analysis of the coexistence of various mechanisms of resistance and their effect on the phenotype of investigated pathogens. It is worth noting that among CARB-S microorganisms we described individual cases of (1) derepression of AmpC cephalosporinase (S53, S54) as well as (2) strains demonstrating ompC-directed polarization of OM transcriptome. However, it must be emphasized that there was no co-occurrence of the aforementioned mechanisms. Moreover, overproduction of AmpC enzyme in S53 and S54 was compensated by ompF-directed OM transcriptome polarization. OM permeability of those two strains was determined by porin with a relatively large transmembrane domain, wherein the electrostatic potential and molecular configuration allows efficient penetration of β-lactam antimicrobials into periplasmic space. We described another unique strain among the CARB-S subpopulation, S62-ST89 which was sequence type dominant in group resistant to carbapenems. However, strain S62 stood out in terms of molecular characteristics—the tested strain did not develop carbapenem-resistance despite the decrease in ompF expression and ompC-directed OM transcriptome polarization. Low-level AmpC expression was the distinguishing feature of strain S62-ST89.

It seems that co-operation among different mechanisms is crucial for exhibiting carbapenem resistance in clinical aspects. Carbapenems are “poor substrates” in relation to most chromosomal and plasmidic AmpC-type isoenzymes (Mammeri et al., 2008, 2010; Jacoby, 2009). However, an increase of carbapenem MIC is often a result of decreased permeability of the OM in conjunction with a significant increase in AmpC expression level and/or mutations affecting the hydrolytic properties of chromosomal β-lactamase. Interestingly, development of clinical resistance conditioned by classical carbapenemases, in many cases also requires an additional mechanism of resistance, e.g., decreased OM permeability. The results obtained by many authors pointed to a slight increase of carbapenem MICs among strains presenting an isolated resistance mechanism—including KPC, IMP, OXA-48, and VIM-type acquired carbapenemases (Cuzon and Naas, 2008; Carrër et al., 2010; Cuzon et al., 2011; Daikos and Markogiannakis, 2011; Poirel et al., 2012). Based on low MIC values of carbapenems, evaluated pathogens were often categorized as sensitive or intermediate in relation to particular agents (Yan et al., 2001; Daikos et al., 2009; Endimiani et al., 2009; Hirsch and Tam, 2010; Kumarasamy et al., 2010; Picão et al., 2013).

Research papers analyzing the impact of permeability disturbances on carbapenem-resistance phenotype development in Gram-negative bacteria showed a great variety of possible OM transcriptome profiles. The decrease of gene expression may cover an isolated decrease of ompC or ompF porin encoding genes, as well as, both major OM proteins (Bialek et al., 2010). Expression level of genes encoding OM proteins is of key importance in case of β-lactam activity, as demonstrated in a study by Doménech-Sánchez et al. (2003) on K. pneumoniae strain CSUB10R, which lost both OmpF, and OmpC proteins. Complementation studies showed significant reduction of β-lactam MIC values in strains with restored OmpF protein. Complemented strain represented an 8-fold decrease in MIC values of imipenem and a 128-fold decrease of cephalosporins and meropenem MIC values. Another project emphasizing key role of OmpF protein was published by Moya-Torres et al. (2014). Authors performed molecular characterization of permeability disorders in Serratia marcescens, and proved that OmpF protein was the most important factor contributing to changes in MIC values of β-lactams.

The results of the research work published by Babouee Flury et al. (2016) on the development of carbapenem-resistance in E. cloacae proved a significant contribution of the chromosomal AmpC cephalosporinase overproduction coupled with impaired OM permeability. The authors linked permeability disorders with relative decrease of gene expression and/or mutations in the structural porin-encoding genes. Nucleotide sequence analysis of genes encoding OmpC and OmpF OM proteins showed the presence of nonsense mutations and deletions within the structural region as well as the presence of insertion sequences disrupting promoters responsible for porin expression. Carbapenem-resistant strains showed a 10–40-fold relative increase in the level of ampC transcripts. In this study we described a relative increase in AmpC cephalosporinase gene expression among CARB-R strains; however, the range of values was ranked from 4.5-fold increase up to expression 1000-fold higher than that of the reference strain. Analysis of relative changes in porin-encoding gene expression level carried out by Babouee Flury et al. (2016) showed a 2.5-fold decrease in ompF level, and a 3-fold decrease in the ompC expression level. The extremely low ompC expression described by the authors amounted to a 160-fold decrease in relation to the reference strain. In this study we described carbapenem-resistance associated with relative decrease of ompF expression with the extreme value of the 50-fold reduction in transcript levels. Another phenomenon described in this study is the shift in the OM porin profile. Carbapenem-resistant E. cloacae showed a tendency to compensatory increase of ompC expression.

In accordance with our results, research work published by Szabó et al. (2006) indicated the involvement of 50-fold decrease in ompF gene expression in carbapenem-resistant E. cloacae. The research project published by Pérez et al. (2007) concerning carbapenem-resistant E. cloacae was based on the analysis of ompF and ompC gene expression levels. The authors described decreased expression of both ompF (5-fold) and ompC (500-fold) genes in resistant strains. The decrease in expression level of both major OM proteins was also recorded in the report published by Koyano et al. (2013), Philippe et al. (2015) and Jaskulski et al. (2013).

Molecular analysis of E. aerogenes exhibiting high MIC of imipenem (8 mg/L) carried out by Fernández-Cuenca et al. (2006) showed two coexisting mechanisms of resistance, a decrease in expression of OM protein (40 kDa) coupled with high AmpC activity. The report prepared by Doumith et al. (2009) was based on molecular analysis of resistance to ertapenem among Enterobacter spp., and Klebsiella spp. isolated in the UK. The coexistence of enzymatic barrier (AmpC overexpression or KPC carbapenemase) in conjunction with impaired permeability of OM was found to be the main cause of ertapenem resistance in E. cloacae. Depending on the degree of resistance to ertapenem, the authors observed various OM protein profiles—a decrease in expression of both major porins, or isolated decrease in ompF expression while maintaining ompC gene function.

Analysis of ertapenem-resistance in E. cloacae isolated in Taiwan indicated the possible participation of active efflux, AmpC derepression, and impaired permeability of OM (Yang et al., 2012). Acquired carbapenemase IMP-8 was detected in 5% of resistant strains, coinciding with the results of this study. Changes in porin-encoding gene expression were observed in 43.4% of strains with various porin genotypes. The largest percentage of resistant E. cloacae showed impaired permeability caused by a decrease in ompF expression level.

Analysis of the basic requirements for the development of carbapenem resistance among E. cloacae strains isolated in China indicated the coexistence of derepressed chromosomal AmpC β-lactamase, a decrease in ompF expression, and the presence of acquired VIM-2 carbapenemase in individual strains (Lee et al., 2012). In the case of Enterobacter spp. isolated in Chile, among different levels of carbapenem resistance, the authors described coexistence of impaired OM permeability with AmpC overexpression (Wozniak et al., 2012). We described single strains (R30, R31, R43, and R44) presenting relatively unchanged porin profile, which were resistant to ertapenem (MIC values from 2 to 8 mg/L). Ertapenem resistance in those E. cloacae strains was probably associated with considerable AmpC overexpression.

In a report published by Novais et al. (2012) considering ertapenem resistance in Enterobacteriaceae, the authors indicated two mechanisms of OM permeability disruption, namely, nonsense mutations and/or insertion sequence (IS) incorporation into structural porin-encoding genes, and production of nonfunctional proteins effecting from mutations in the third loop region of the transmembrane channel. Reuter et al. (2013) reported a frame shift and/or stop codon presence in the ompF gene of resistant pathogens. Goessens et al. (2013) showed that a decreased expression of two major OM proteins may not lead to the development of carbapenem resistance. In accordance with this finding, we described the case of a single strain, S67, showing a relatively decreased expression of both ompF and ompC, which retained susceptibility to carbapenems despite coexistent ESBL production. Relatively increased ertapenem MIC (0.125 mg/L) was the only characteristic feature of strain S67.

Alterations of OM protein balance (OmpF/OmpC) in the context of β-lactam resistance development have not been widely reported in the literature. However, there are numerous reports indicating porin balance regulatory cascade as an adaptive mechanism of Enterobacteriaceae and other Gram-negative rods, utilized in response to adverse environmental conditions such as, high osmotic pressure or changes in the availability of oxygen (Nikaido, 2003; Ruiz et al., 2006; Vogel and Papenfort, 2006). It is possible for microorganisms to regulate the OmpF-OmpC ratio, thereby choosing porins with preferable transmembrane channel diameter, electrostatic potential, and the molecular configuration inside the channel. Regulatory cascades can also allow pathogens to take over permeability by the minor porins such as OmpY or OmpK37 (Knopp and Andersson, 2015; Bystritskaya et al., 2016). Various regulatory cascades can be launched in response to changing environmental conditions. Among possible mechanisms involved in decreasing OM permeability due to OmpC-directed OM porin balance, we can mention the increased expression of bolA morphogene responsible for adaptive stress response in Enterobacteriaceae (Freire et al., 2006), and the TolC, LamB, and Dps proteins which can significantly influence OM protein network (Yang et al., 2011). Handling of the OM protein balance according to environmental factors may also be conditioned by the two-component regulatory system OmpR-EnvZ (Chhabra et al., 2012; Shimada et al., 2015). Another mechanism influencing the relationship between produced OM proteins is a two-component system CpxA-CpxR closely associated with the activity of the AtpB protein, the β-subunit of ATP synthase localized in the plasma membrane (Lin et al., 2012). Studies conducted by Batchelor et al. (2005) based on controlled mutagenesis showed that phosphorylation of the CpxR regulator in “wild-type” strains activates histidine kinase CpxA, and leads to transient polarization of OM protein balance in response to environmental stress. Moreover, the authors proved that mutations within histidine kinase CpxA showed the possible fixation of OmpC-directed OM polarization. It can be assumed that factors disturbing the physiological regulatory cascade may be associated with consistent OM protein balance polarization toward OmpC with restrictive channel or abnormal expression of both major porins (Malickbasha et al., 2010; Yang et al., 2011; Tängdén et al., 2013).

Molecular analysis of E. aerogenes strains isolated during imipenem treatment revealed the potential role of ompC-directed OM protein polarization (Lavigne et al., 2012). Analyzed strains with permeability disturbances were characterized by resistance to ertapenem, and elevated MIC values of imipenem. Moreover, the authors described strains that lost both OmpF and OmpC proteins, and developed resistance to imipenem in the clinical aspect. Studies on the expression profile of porin-encoding genes among MDR K. pneumoniae performed by Hasdemir et al. (2004) showed interdependence between two major porins. For most analyzed MDR microorganisms loss of OmpF expression was accompanied with the retained production of the OmpC protein conditioning permeability of the OM.

Recently published reports indicated a high incidence of carbapenem-resistant Enterobacteriaceae without participation of any acquired carbapenemase. The authors indicated comorbidity of OM permeability disorders with the presence of AmpC and/or extended-spectrum β-lactamases (Hasdemir et al., 2004; Drew et al., 2013; Ammenouche et al., 2014). Acquired carbapenemase participation in the development of resistance to carbapenems among Enterobacteriaceae was estimated in a report published by Robert et al. (2014). The analyses included pathogens resistant to at least one carbapenem isolated primarily from urinary and respiratory tracts of patients hospitalized in 71 medical centers in France. Carbapenem-resistant E. cloacae strains, the subject of this paper, were also obtained in the largest proportion from the urinary and respiratory tracts. In the aforementioned report, E. cloacae were the predominant pathogen (58.2%), and resistance to carbapenems was not conditioned by the presence of acquired carbapenemases. Among all microorganisms subjected to molecular analysis, only 12.6% of carbapenem-resistant strains possessed acquired carbapenemases. In the case of the remaining pathogens, resistance was associated with impaired OM permeability.

Here we report the co-operation of three distinct carbapenem-resistance mechanisms—production of OXA-48 carbapenemase, AmpC overproduction, and alterations in outer membrane (OM) transcriptome balance. Carbapenem-resistant E. cloacae subpopulations were characterized by (1) downregulation of ompF gene, which encodes protein with extensive transmembrane channels, and (2) the polarization of OM transcriptome-balance, which was sloped toward ompC gene, encoding proteins recently reported to possess restrictive transmembrane channels. The growing prevalence of pathogens resistant to most or even all currently available antimicrobial agents heralds the potential risk of a future “post-antibiotic era” (Falagas and Bliziotis, 2007; Livermore, 2009; Hornsey et al., 2010; Chen et al., 2011; Bergen et al., 2012; Diena et al., 2012; Majewski et al., 2012, 2014b; Yahav et al., 2012; Linkevicius et al., 2013; Veleba et al., 2013; Deng et al., 2014). Great effort needs to be taken to explore the background of resistance to antimicrobials of “last-resort.”

Author contributions

PM, PW, JN, ET substantially contributed to: conception of the submitted research paper—designing and validation of experiments (PCR and qPCR)—data acquisition and interpretation (antimicrobial susceptibility testing, Sanger sequencing, qPCR, bioinformatics)—revising the manuscript. DO, AS, OK, PS substantially contributed to:—conception of the submitted research paper—validation of designed experiments (phenotypic methods)—data acquisition and interpretation (antimicrobial susceptibility testing, nucleic acid purification, PCR, bioinformatics)—drafting the manuscript.

Funding

This study was conducted with the use of equipment purchased by Medical University of Bialystok as part of the OP DEP 2007-2013, Priority Axis I.3, contract No POPW.01.03.00-20-022/09. The paper submitted was supported in part by departmental and The Leading National Research Centre sources.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank Steven J. Snodgrass for editorial assistance, and Applied Maths NV (Sint-Martens-Latem, Belgium) for an evaluation license of BioNumerics 7.6 software, and the kind permission to publish results.

References

  1. Ammenouche N., Dupont H., Mammeri H. (2014). Characterization of a novel AmpC β-lactamase produced by a carbapenem-resistant Cedecea davisae clinical isolate. Antimicrob. Agents Chemother. 58, 6942–6945. 10.1128/AAC.03237-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Babouee Flury B., Ellington M. J., Hopkins K. L., Turton J. F., Doumith M., Loy R., et al. (2016). Association of novel nonsynonymous single nucleotide polymorphism in ampD with cephalosporin resistance and phylogenetic variations in ampC, ampR, ompF and ompC in Enterobacter cloacae that are highly resistant to carbapenems. Antimicrob. Agents Chemother. 60, 2383–2390. 10.1128/AAC.02835-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Batchelor E., Walthers D., Kenney L. J., Goulian M. (2005). The Escherichia coli CpxA-CpxR envelope stress response system regulates expression of the porins ompF and ompC. J. Bacteriol. 187, 5723–5731. 10.1128/JB.187.16.5723-5731.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bergen P. J., Landersdorfer C. B., Zhang J., Zhao M., Lee H. J., Nation R. L., et al. (2012). Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn. Microb. Infect. Dis. 74, 213–223. 10.1016/j.diagmicrobio.2012.07.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bialek S., Lavigne J. P., Chevalier J., Marcon E., Leflon-Guibout V., Davin A., et al. (2010). Membrane efflux and influx modulate both multidrug resistance and virulence in Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob. Agents Chemother. 54, 4373–4378. 10.1128/AAC.01607-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bystritskaya E., Stenkowa A., Chistuylin D., Chernysheva N., Khomenko V., Anastyuk S., et al. (2016). Adaptive responses of outer membrane porin balance of Yersinia ruckeri under different incubation temperature, osmolality, and oxygen availability. Microbiologyopen 5, 597–603. 10.1002/mbo3.354 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carrër A., Poirel L., Yilmaz M., Akan O. A., Fericha C., Cuzon G., et al. (2010). Spread of OXA-48-encoding plasmid in turkey and beyond. Antimicrob. Agents Chemother. 54, 1369–1373. 10.1128/AAC.01312-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cerceo E., Deitelzweig S. B., Sherman B. M., Amin A. N. (2016). Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb. Drug Resist. 22, 412–431. 10.1089/mdr.2015.0220 [DOI] [PubMed] [Google Scholar]
  9. Chen L. Y., Chen T. C., Chen Y. H., Lin C. Y., Lu P. L. (2011). Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. J. Microbiol. Immunol. Infect. 44, 352–357. 10.1016/j.jmii.2011.01.033 [DOI] [PubMed] [Google Scholar]
  10. Chhabra G., Upadhyaya T., Dixit A. (2012). Molecular cloning, sequence analysis and structure modeling of OmpR, the response regulator of Aeromonas hydrophila. Mol. Biol. Rep. 39, 41–50. 10.1007/s11033-011-0708-3 [DOI] [PubMed] [Google Scholar]
  11. Cuzon G., Naas T. (2008). Plasmid-encoded carbapenem-hydrolyzing β-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob. Agents Chemother. 52, 3463–3464. 10.1128/AAC.00543-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cuzon G., Ouanich J., Gondret R., Naas T., Nordmann P. (2011). Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob. Agents Chemother. 55, 2420–2423. 10.1128/AAC.01452-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Daikos G. L., Markogiannakis A. (2011). Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin. Microbiol. Infect. 17, 1135–1141. 10.1111/j.1469-0691.2011.03553.x [DOI] [PubMed] [Google Scholar]
  14. Daikos G. L., Petrikkos P., Psichogiou M., Kosmidis C., Vryonis E., Skoutelis A., et al. (2009). Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53, 1868–1873. 10.1128/AAC.00782-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Davin-Regli A., Pagès J. M. (2015). Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment. Front. Microbiol. 6:392. 10.3389/fmicb.2015.00392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Delcour A. H. (2009). Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta 1794, 808–816. 10.1016/j.bbapap.2008.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Deng M., Zhu M. H., Li J. J., Bi S., Sheng Z. K., Hu F. S., et al. (2014). Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from Chinese university hospital. Antimicrob. Agents Chemother. 58, 297–303. 10.1128/AAC.01727-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Diena S. M., Merhej V., Henry M., Filali A. E., Roux V., Robert C., et al. (2012). The rhizome of the multidrug-resistant Enterobacter aerogenes genome reveals how new “Killer Bugs” are created because of sympatric lifestyle. Mol. Biol. Evol. 30, 369–383. 10.1093/molbev/mss236 [DOI] [PubMed] [Google Scholar]
  19. Doménech-Sánchez A., Martínez-Martínez L., Hernandéz-Allés S., del Carmen Conejo M., Pascual A., Tomás J. M., et al. (2003). Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob. Agents Chemother. 47, 3332–3335. 10.1128/AAC.47.10.3332-3335.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dortet L., Poirel L., Nordmann P. (2012). Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using biochemical test. Antimicrob. Agents Chemother. 56, 6437–6440. 10.1128/AAC.01395-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Doumith M., Ellington M. J., Livermore D. M., Woodford N. (2009). Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 63, 659–667. 10.1093/jac/dkp029 [DOI] [PubMed] [Google Scholar]
  22. Drew R. J., Turton J. F., Hill R. L. R., Livermore D. M., Woodford N., Paulus S., et al. (2013). Emergence of carbapenem-resistant Enterobacteriaceae in a UK paediatric hospital. J. Hosp. Infect. 84, 300–304. 10.1016/j.jhin.2013.05.003 [DOI] [PubMed] [Google Scholar]
  23. Ellington M. J., Kistler J., Livermore D. M., Woodford N. (2007). Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J. Antimicrob. Chemother. 59, 321–322. 10.1093/jac/dkl481 [DOI] [PubMed] [Google Scholar]
  24. Endimiani A., Hujer A. M., Perez F. (2009). Characterization of bla-KPC containing Klebsiella pneumoniae isolates detected in different institutions in eastern United States. J. Antimicrob. Chemother. 63, 427–437. 10.1093/jac/dkn547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Falagas M. E., Bliziotis I. A. (2007). Pandrug-resistant Gram-negative bacteria: the dawn of the post antibiotic era? Int. J. Antimicrob. Agents 29, 630–636. 10.1016/j.ijantimicag.2006.12.012 [DOI] [PubMed] [Google Scholar]
  26. Fernández-Cuenca F., Rodríguez-Martínez J. M., Martínez-Martínez L., Pascual A. (2006). In vivo selection of Enterobacter aerogenes with reduced susceptibility to cefepime and carbapenems associated with decreased expression of a 40 kDa outer membrane protein and hyperproduction of AmpC beta-lactamase. Int. J. Antimicrob. Agents 27, 549–552. 10.1016/j.ijantimicag.2006.01.005 [DOI] [PubMed] [Google Scholar]
  27. Findlay J., Hamouda A., Dancer S. J., Amyes S. G. (2012). Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy. Clin. Microb. Infect. 18, 140–146. 10.1111/j.1469-0691.2011.03515.x [DOI] [PubMed] [Google Scholar]
  28. Fischbach M. A. (2011). Combination therapies for combating antimicrobial resistance. Curr. Opin. Microbiol. 14, 519–523. 10.1016/j.mib.2011.08.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Freire P., Vieira H. L. A., Furtado A. R., De Pedro M. A., Arraiano M. R. (2006). Effect of the morphogene bolA on the permeability of the Escherichia coli outer membrane. FEMS Microbiol. Lett. 206, 106–111. 10.1111/j.1574-6968.2006.00307.x [DOI] [PubMed] [Google Scholar]
  30. Giamarellou H. (2010). Multidrug-resistant Gram-negative bacteria: how to treat and for how long? Int. J. Antimicrob. Agents 36(Suppl. 2), S50–S54. 10.1016/j.ijantimicag.2010.11.014 [DOI] [PubMed] [Google Scholar]
  31. Goessens W. H., van der Bij A. K., van Boxtel R., Pitout J. D., van Ulsen P., Melles D. C., et al. (2013). Antibiotic trapping by plasmid-encoded CMY-2 β-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob. Agents Chemother. 57, 3941–3949. 10.1128/AAC.02459-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Hasdemir U. O., Chevalier J., Nordmann P., Pagès J. M. (2004). Detection and prevalence of active drug efflux mechanism in various multidrug-resistant klebsiella pneumoniae strains from Turkey. J. Clin. Microbiol. 42, 2701–2706. 10.1128/JCM.42.6.2701-2706.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hawkey P. M., Jones A. M. (2009). The changing epidemiology of resistance. J. Antimicrob. Chemother. 64(Suppl. 1), i3–i10. 10.1093/jac/dkp256 [DOI] [PubMed] [Google Scholar]
  34. Hirsch E. B., Tam V. H. (2010). Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65, 1119–1126. 10.1093/jac/dkq108 [DOI] [PubMed] [Google Scholar]
  35. Hornsey M., Ellington M. J., Doumith M., Hudson S., Livermore D. M., Woodford N. (2010). Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. J. Antimicrob. Chemother. 63, 479–482. 10.1093/jac/dkp475 [DOI] [PubMed] [Google Scholar]
  36. Jacoby G. A. (2009). AmpC beta-lactamases. Clin. Microbiol. Rev. 22, 161–182. 10.1128/CMR.00036-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. James C. E., Mahendran K. R., Molitor A., Bolla J. M., Bessonov A. N., Winterhalter M., et al. (2009). How beta-lactam antibiotics enter bacteria: a dialogue with porins. PLoS ONE 4:e5453. 10.1371/journal.pone.0005453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Jaskulski M. R., Medeiros B. C., Borges J. V., Zalewsky R., Fonseca M. E., Marinowic D. R., et al. (2013). Assessment of extended-spectrum β-lactamase, KPC carbapenemase and porin resistance mechanisms in clinical samples of Klebsiella pneumoniae and Enterobacter spp. Int. J. Antimicrob. Agents 42, 76–79. 10.1016/j.ijantimicag.2013.03.009 [DOI] [PubMed] [Google Scholar]
  39. Karaiskos I., Giamarellou H. (2014). Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin. Pharmacother. 15, 1315–1370. 10.1517/14656566.2014.914172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Kaye K. S., Pogue J. M. (2015). Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy 35, 949–962. 10.1002/phar.1636 [DOI] [PubMed] [Google Scholar]
  41. Khameneh B., Diab R., Ghazvini K., Fazly Bazzaz B. S. (2016). Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Micob. Pathog. 95, 32–42. 10.1016/j.micpath.2016.02.009 [DOI] [PubMed] [Google Scholar]
  42. Knopp M., Andersson D. I. (2015). Amelioration of the fitness cost of antibiotic resistance due to reduced outer membrane permeability by upregulation of alternative porins. Mol. Biol. Evol. 32, 3252–3263. 10.1093/molbev/msv195 [DOI] [PubMed] [Google Scholar]
  43. Koyano S., Saito R., Nagai R., Tatsuno K., Okugawa S., Okamura N., et al. (2013). Molecular characterization of carbapenemase-producing clinical isolates of Enterobacteriaceae in a teaching hospital, Japan. J. Med. Microbiol. 62, 446–450. 10.1099/jmm.0.050708-0 [DOI] [PubMed] [Google Scholar]
  44. Kumarasamy K. K., Toleman M. A., Walsh T. R., Bagaria J., Butt F., Balakrishnan R., et al. (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological and epidemiological study. Lancet Infect. Dis. 10, 597–602. 10.1016/S1473-3099(10)70143-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lavigne J. P., Sotto A., Nicolas-Chanoine M. H., Bouziges N., Bourg G., Davin-Regli A., et al. (2012). Membrane permeability, a pivotal function involved in antibiotic resistance and virulence in Enterobacter aerogenes clinical isolates. Clin. Microbiol. Infect. 18, 539–545. 10.1111/j.1469-0691.2011.03607.x [DOI] [PubMed] [Google Scholar]
  46. Lee Y., Choi H., Yum J. H., Kang G., Bae I. K., Jeong S. H., et al. (2012). Molecular mechanisms of carbapenem resistance in Enterobacter cloacae clinical isolates from Korea and clinical outcome. Ann. Clin. Lab. Sci. 42, 281–286. [PubMed] [Google Scholar]
  47. Lin X., Wang C., Guo C., Tian Y., Li H., Peng X. (2012). Differential regulation of OmpC and OmpF by AtpB in Escherichia coli exposed to nalidixic acid and chlortetracycline. J. Proteomics 75, 5898–5910. 10.1016/j.jprot.2012.08.016 [DOI] [PubMed] [Google Scholar]
  48. Linkevicius M., Sandegren L., Andersson D. I. (2013). Mechanisms and fitness cost of tigecycline resistance in Escherichia coli. J. Antimicrob. Chemother. 68, 2809–2819. 10.1093/jac/dkt263 [DOI] [PubMed] [Google Scholar]
  49. Livermore D. M. (2009). Has the era of untreatable infection arrived? J. Antimicrob. Chemother. 64, 29–36. 10.1093/jac/dkp255 [DOI] [PubMed] [Google Scholar]
  50. MacVane S. H. (2017). Antimicrobial resistance in the intensive care unit: a focus on gram-negative bacterial infections. J. Intensive Care Med. 32, 25–37. 10.1177/0885066615619895 [DOI] [PubMed] [Google Scholar]
  51. Majewski P., Sacha P. T., Wieczorek P., Ojdana D., Michalska A., Tryniszewska E. (2012). New Delhi-Metallo-β-Lactamases – the dawn of the post-antibiotic era? Prog. Health Sci. 2, 153–160. [Google Scholar]
  52. Majewski P., Wieczorek P., Ojdana D., Sacha P. T., Wieczorek A., Tryniszewska E. A. (2014b). In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene. Scand. J. Infect. Dis. 46, 260–264. 10.3109/00365548.2013.865141 [DOI] [PubMed] [Google Scholar]
  53. Majewski P., Wieczorek P., Sacha P. T., Frank M., Juszczyk G., Ojdana D., et al. (2014a). Emergence of OXA-48 carbapenemase-producing Enterobacter cloacae ST89 infection in Poland. Int. J. Infect. Dis. 25, 107–109. 10.1016/j.ijid.2014.02.024 [DOI] [PubMed] [Google Scholar]
  54. Malickbasha M., Arunachalam R., Senthilkumar B., Rajasekarapandian M., Annadurai G. (2010). Effect of ompR gene mutation in expression of ompC and ompF of Salmonella typhi. Interdiscip. Sci. 2, 157–162. 10.1007/s12539-010-0067-0 [DOI] [PubMed] [Google Scholar]
  55. Mammeri H., Guillon H., Eb F., Nordmann P. (2010). Phenotypic and biochemical comparison of carbapenem-hydrolyzing activities of five plasmid-borne AmpC beta-lactamases. Antimicrob. Agents Chemother. 54, 4556–4560. 10.1128/AAC.01762-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Mammeri H., Nordmann P., Berkani A., Eb F. (2008). Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol. Lett. 282, 238–240. 10.1111/j.1574-6968.2008.01126.x [DOI] [PubMed] [Google Scholar]
  57. Miyoshi-Akiyama T., Hayakawa K., Ohmagari N., Shimojima M., Kirikae T. (2013). Multilocus sequence typing (MLST) for characterization of Enterobacter cloacae. PLoS ONE 8:e66358. 10.1371/journal.pone.0066358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Moya-Torres A., Mulvey M. R., Kumar A., Oresnik I. J., Brassinga A. K. (2014). The lack of OmpF, but not OmpC, contributes to increased antibiotic resistance in Serratia marcescens. Microbiology 160, 1882–1892. 10.1099/mic.0.081166-0 [DOI] [PubMed] [Google Scholar]
  59. Nikaido H. (2003). Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67, 593–656. 10.1128/MMBR.67.4.593-656.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Nikaido H. (2009). Multidrug resistance in bacteria. Annu. Rev. Biochem. 78, 119–146. 10.1146/annurev.biochem.78.082907.145923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Novais A., Rodrigues C., Branguinho R., Antunes P., Grosso F., Boaventura L., et al. (2012). Spread of an OmpK36-modified ST15 Klebsiella pneumoniae variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. Eur. J. Clin. Microbiol. Infect. Dis. 31, 3057–3063. 10.1007/s10096-012-1665-z [DOI] [PubMed] [Google Scholar]
  62. Papp-Wallace K. M., Endimiani A., Taracila M. A., Bonomo R. A. (2011). Carbapenems: past, present and future. Antimicrob. Agents Chemother. 55, 4943–4960. 10.1128/AAC.00296-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Pérez A., Canle D., Latasa C., Poza M., Beceiro A., Tomás Mdel M., et al. (2007). Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. Antimicrob. Agents Chemother. 51, 3247–3253. 10.1128/AAC.00072-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Pfaffl M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acid. Res. 29, 2001–2007. 10.1093/nar/29.9.e45 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Philippe N., Maigre L., Santini S., Pinet E., Claverie J. M., Davin-Régli A. V., et al. (2015). In vivo evolution of bacterial resistance in two cases of Enterobacter aerogenes infections during treatment with imipenem. PLoS ONE 10:e0138828. 10.1371/journal.pone.0138828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Picão R. C., Jones R. N., Mendes R. E., Castanheira M. (2013). Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods. J. Clin. Microbiol. 51, 2388–2390. 10.1128/JCM.00640-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Poirel L., Potron A., Nordmann P. (2012). OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67, 1597–1606. 10.1093/jac/dks121 [DOI] [PubMed] [Google Scholar]
  68. Poole K. (2011). Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. 2:65. 10.3389/fmicb.2011.00065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Reuter S., Ellington M. J., Cartwright E. J. P., Köser C. U., Török M. E., Gouliouris T., et al. (2013). Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern. Med. 173, 1397–1404. 10.1001/jamainternmed.2013.7734 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Review on Antimicrobial Resistance (2014). Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth Nations. Welcome Trust. [Google Scholar]
  71. Robert J., Pantel A., Merens A., Lavigne J. P., Nicolas-Chanoine M. H. (2014). Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-2012. J. Antimicrob. Chemother. 69, 2706–2712. 10.1093/jac/dku208 [DOI] [PubMed] [Google Scholar]
  72. Ruiz N., Kahne D., Silhavy T. J. (2006). Advances in understanding bacterial outer-membrane biogenesis. Nat. Rev. Microbiol. 4, 57–66. 10.1038/nrmicro1322 [DOI] [PubMed] [Google Scholar]
  73. Sacha P. T., Ojdana D., Wieczorek P., Kłosowska W., Krawczyk M., Czaban S., et al. (2012). Genetic similarity and antimicrobial susceptibility of Klebsiella pneumoniae producing carbapenemase (KPC-2) isolated in different clinical specimens received from University Hospital in Northeastern Poland. Afr. J. Microb. Res. 6, 6888–6892. 10.5897/AJMR12.266 [DOI] [Google Scholar]
  74. Shimada T., Takada H., Yamamoto K., Ishihama A. (2015). Expanded roles of two-component response regulator OmpR in Escherichia coli: genomic SELEX search for novel regulation targets. Genes Cells 20, 915–931. 10.1111/gtc.12282 [DOI] [PubMed] [Google Scholar]
  75. Szabó D., Silveira F., Hujer A. M., Bonomo R. A., Hujer K. M., Marsh J. W., et al. (2006). Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae. Antimicrob. Agents Chemother. 50, 2833–2835. 10.1128/AAC.01591-05 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Tamma P. D., Cosgrove S. E., Maragakis L. L. (2012). Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microb. Rev. 25, 450–470. 10.1128/CMR.05041-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Tängdén T., Adler M., Cars O., Sandegren L., Löwdin E. (2013). Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. J. Antimicrob. Chemother. 68, 1319–1326. 10.1093/jac/dkt044 [DOI] [PubMed] [Google Scholar]
  78. Tängdén T., Giske G. C. (2015). Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J. Intern. Med. 277, 501–512. 10.1111/joim.12342 [DOI] [PubMed] [Google Scholar]
  79. The European Committee on Antimicrobial Susceptibility Testing (2015). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 5.0. [Google Scholar]
  80. Veleba M., De Majumdar S., Hornsey M., Woodford N., Schneiders T. (2013). Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J. Antimicrob. Chemother. 68, 1011–1018. 10.1093/jac/dks530 [DOI] [PubMed] [Google Scholar]
  81. Vogel J., Papenfort K. (2006). Small non-coding RNAs and the bacterial outer membrane. Curr. Opin. Microbiol. 9, 605–611. 10.1016/j.mib.2006.10.006 [DOI] [PubMed] [Google Scholar]
  82. Wozniak A., Villagra N. A., Undabarrena A., Gallardo N., Keller N., Moraga M., et al. (2012). Porin alterations present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. J. Med. Microbiol. 61, 1270–1279. 10.1099/jmm.0.045799-0 [DOI] [PubMed] [Google Scholar]
  83. Yahav D., Farbman L., Leibovici L., Paul M. (2012). Colistin: new lessons on an old antibiotic. Clin. Microbiol. Infect. 18, 18–29. 10.1111/j.1469-0691.2011.03734.x [DOI] [PubMed] [Google Scholar]
  84. Yan J. J., Ko W. C., Tsai S. H., Wu H. M., Wu J. J. (2001). Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying blaIMP-8 in a university medical center in Taiwan. J. Clin. Microbiol. 39, 4433–4439. 10.1128/JCM.39.12.4433-4439.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Yang F. C., Yan J. J., Hung K. H., Wu J. J. (2012). Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital. J. Clin. Microbiol. 50, 223–226. 10.1128/JCM.01263-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Yang J. N., Wang C., Guo C., Peng X. X., Li H. (2011). Outer membrane proteome and its regulation networks in response to glucose concentration changes in Escherichia coli. Mol. Biosyst. 7, 3087–3093. 10.1039/c1mb05193h [DOI] [PubMed] [Google Scholar]
  87. Ziervogel B. K., Roux B. (2013). The binding of Antibiotics in OmpF Porin. Structure 21, 76–87. 10.1016/j.str.2012.10.014 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Microbiology are provided here courtesy of Frontiers Media SA

RESOURCES